SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The Mullen Army Token originated from a dedicated community of retail investors who faced challenges in the traditional stock market. We united to create a cryptocurrency that embodies our principles and aspirations for a fair financial system.     We provide a platform for retail investors to engage in a transparent and fair financial market. Our efforts include grassroots marketing, community engagement, and educational content to empower our investors.

MullenArmy

The MULN symbol is trending due to significant community discussion surrounding a new 'Mullen Army' crypto token that leverages the controversial Mullen Automotive name; many investors are expressing strong skepticism, citing the stock's history of reverse splits and dilution, while some proponents claim the token offers utility and a revolutionary movement.

We're a deflationary token that builds utility around our BTC and ETH reserves.  Our main goal is to onboard newbies in the friendliest and safest way, that's why we launched our NFT book (definitely for dummies) on five chains one year ago.  Our new swap generates revenue that combined with our taxes allow us to grow at a slow but steady pace; We're completely sustainable because our monthly expenses are really low.

PiggyCoinBSC

PiggyCoinBSC ($PIGGYC) is trending as its community actively engages in X spaces, highlighting its unique tokenomics that include $BTC and $ETH strategic reserves, and the utility of its new multi-chain swap platform, Swappy. Despite strong bullish sentiment from supporters, some community members are voicing concerns and labeling it a scam.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending sharply as its highly positive Phase 2 axSpA clinical data, robust financial updates, and institutional accumulation fuel intense investor anticipation, positioning sonelokimab as a potential best-in-class drug and igniting buyout speculation ahead of its upcoming Investor Day.

NEAR Protocol is the blockchain for AI. A high-performance, AI-native platform built to power the next generation of decentralized applications and intelligent agents. It provides the infrastructure AI needs to transact, operate, and interact across Web2 and Web3. NEAR combines three core elements: User-Owned AI, which ensures agents act in users’ best interests; Intents and Chain Abstraction, which eliminate blockchain complexity for seamless, goal-driven transactions across chains; and a sharded blockchain architecture that delivers the scalability, speed, and low-cost execution needed for real-world AI and Web3 use. This integrated stack makes NEAR the foundation for building secure, user-owned, AI-native applications at internet scale.

Near

NEAR is trending driven by institutional interest following a Grayscale S-1 filing for a NEAR Trust, alongside its expanding utility in cross-chain liquidity via 'NEAR Intents' and significant advancements in AI integration. Despite recent price volatility that has divided community sentiment, many are accumulating, banking on its reduced token inflation and strategic position in the AI-crypto ecosystem.

Vicor Corp. engages in the design, development, manufacture, and marketing of modular power components. The firm provides complete power systems based upon a portfolio of patented technologies. Its products include AC-DC converters, power systems, and accessories. The company was founded by Patrizio Vinciarelli in 1981 and is headquartered in Andover, MA.

Vicor Corp.

Vicor is surging following a substantial earnings beat and optimistic outlook for record revenues in 2026, fueled by its patented high-density power solutions crucial for AI data centers and successful IP licensing; however, some technical traders are eyeing consolidation after the rapid ascent.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is actively trending following FDA approval for Bysanti, an antipsychotic granted New Chemical Entity (NCE) status with patent protection until 2044. The community views this unexpected long-term exclusivity as a transformative event, anticipating significant analyst re-ratings and potential multi-billion dollar buyout offers from major pharmaceutical companies seeking to address their own patent cliffs, alongside excitement for Vanda's broader pipeline, including a GLP-1 related nausea drug.

Frontera Energy Corp. engages in the exploration, development, production, transportation, storage, and sale of oil and natural gas. It operates interests in exploration and production blocks in Colombia, Ecuador and Guyana, and pipeline and port facilities in Colombia. The company was founded on April 10, 1985 and is headquartered in Calgary, Canada.

Frontera Energy Corporation - Ordinary Shares New

Frontera Energy is trending due to the anticipated cash distribution from the sale of its Colombian E&P assets and an ongoing strategic review of its remaining infrastructure business, with investors keenly focused on the vast potential and contentious dispute over its Corentyne block in the highly sought-after Guyana-Suriname Basin.

SSgA Active Trust - State Street Consumer Discretionary Select Sector SPDR ETF

Consumer Discretionary Select Sector SPDR Fund

The Consumer Discretionary sector (XLY) is trending due to immediate shifts in tariff policies under President Trump, which are creating significant uncertainty around consumer spending and corporate costs. Community discussion reflects mixed views on consumer resilience, with some anticipating higher prices and strain on demand, while others eye potential 'risk-on' opportunities for major constituents like Amazon and Tesla.

$SWEAT is the beating heart of the Movement Economy—a groundbreaking token that transforms physical activity into real-world value. Minted through movement, $SWEAT rewards your steps with a crypto asset that you can earn, trade, or grow. The team states that their app has increased their users’ physical activity by an average of 20%, creating a healthier society and reducing burdens on global healthcare systems. With over 20 million holders, SWEAT is eliminating barriers and making Web3 accessible to everyone, one step at a time.

Sweat Economy

Sweat Economy ($SWEAT) is trending amid active community discussion regarding its "move-to-earn" utility and speculation on its future valuation. Investors are divided between those accumulating with long-term hopes for a rebound and those cautioning against its volatile nature, often noting its association with NEAR Protocol.

Vanguard Group, Inc. - Vanguard Value ETF

Vanguard Value ETF

The Vanguard Value ETF ($VTV) is trending as value stocks surge to new all-time highs, signaling a notable market rotation and outperformance compared to growth sectors. The community is actively discussing VTV as a strong, long-term holding poised for continued strength amidst shifting market dynamics.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Jupiter Asset Management Ltd. Sells 116,575 Shares of Catalyst Pharmaceuticals, Inc. $CPRX

Jupiter Asset Management Ltd. decreased its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 22.5% during the third quarter, according to the company in its most recent...

Catalyst Pharmaceuticals, Inc. $CPRX Shares Sold by Skandinaviska Enskilda Banken AB publ

Skandinaviska Enskilda Banken AB publ trimmed its stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 39.3% during the third quarter, according to its most recent filing...

Aberdeen Group plc Has $12.46 Million Stake in Catalyst Pharmaceuticals, Inc. $CPRX

Aberdeen Group plc lessened its stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 8.2% during the third quarter, according to the company in its most recent filing with...

BioCryst Pharmaceuticals (BCRX) Earnings Expected to Grow: Should You Buy?

BioCryst (BCRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Value Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Analysts Estimate Catalyst Pharmaceutical (CPRX) to Report a Decline in Earnings: What to Look Out for

Catalyst (CPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Catalyst Pharmaceuticals (CPRX) Expected to Announce Earnings on Wednesday

Catalyst Pharmaceuticals (NASDAQ:CPRX) will be releasing its Q4 2025 earnings before the market opens on Wednesday, February 25. (View Earnings Report at...

Public Sector Pension Investment Board Grows Stock Holdings in Catalyst Pharmaceuticals, Inc. $CPRX

Public Sector Pension Investment Board boosted its stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 10.8% during the third quarter, according to the company in its...

Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Tops Revenue Estimates

Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of +1.47% and +3.27%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Allianz Asset Management GmbH Cuts Stake in Catalyst Pharmaceuticals, Inc. $CPRX

Allianz Asset Management GmbH cut its stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 23.1% in the 3rd quarter, according to its most recent disclosure with the...

Catalyst Pharmaceuticals, Inc. is a commercial-stage, patient-centric biopharmaceutical company, which focuses on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult to treat diseases. The company was founded by Hubert E. Huckel and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.

CPRX
Catalyst Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest CPRX News

CPRXCatalyst Pharmaceuticals Inc